Welcome to our dedicated page for Intest SEC filings (Ticker: INTT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The inTEST Corporation (INTT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. inTEST, a global supplier of test and process technology solutions for semiconductor, automotive/EV, defense/aerospace, industrial, life sciences, and safety/security markets, uses these filings to report financial results, corporate actions, and shareholder matters.
Recent Form 8-K filings show how inTEST reports material events such as the release of quarterly financial results and the outcomes of its annual meeting of stockholders. For example, the company has filed current reports to furnish press releases covering results for quarters ended June 30 and September 30, and to disclose voting results on director elections, auditor ratification, and advisory votes on executive compensation and the frequency of such votes.
In addition to current reports, investors typically look to inTEST’s annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on revenue by market and segment, gross margin, operating expenses, net income or loss, and non-GAAP measures such as adjusted net earnings and adjusted EBITDA. These periodic reports also explain how management uses orders and backlog as key performance indicators and provide narrative discussion of market conditions, diversification efforts, and cost management.
On Stock Titan, SEC documents for INTT are supplemented with AI-powered summaries that highlight the main points of lengthy filings, such as 10-K and 10-Q reports. The platform also surfaces real-time updates from EDGAR, helping users quickly identify new 8-Ks and other submissions. For those monitoring governance and compensation, proxy-related disclosures and shareholder vote results are available, while Form 4 and related insider transaction filings can be reviewed to see reported trading activity by directors and officers.
InTest Corporation announced that Richard N. Grant, Jr. has stepped down as President, Chief Executive Officer and director, effective immediately, in accordance with his 2020 offer letter and not due to any disagreement over operations, policies or practices. He is eligible for severance equal to 12 months of base salary, conditioned on signing a separation and release agreement.
The Board appointed Richard Rogoff, previously Vice President of Corporate Development, as President, CEO and director effective March 31, 2026. Under a new agreement, he will receive a $375,000 annual base salary, a 2026 target bonus equal to 65% of base salary, and performance-vesting stock options for up to 300,000 shares with a 10-year term, vesting based on share price performance over a three-year period.
INTEST CORP President and CEO Richard B. Rogoff received a grant of stock options for 300,000 shares of common stock at an exercise price of $13.65 per share. The options expire on March 31, 2036 and were granted under the inTEST Corporation 2023 Stock Incentive Plan in a transaction exempt under Rule 16b-3.
According to the footnotes, this option will vest on the third anniversary of the grant date if the volume weighted average price of the common stock over the final 20 consecutive trading days before that date exceeds specified prices. Rogoff also holds 3,030 restricted stock units that convert one-for-one into common stock and vest in equal installments on March 17, 2027, 2028 and 2029, along with several prior option grants and 12,152 shares of common stock held directly.
inTEST Corp President & CEO Richard N. Grant Jr. reported multiple dispositions of Common Stock on March 31, 2026, all coded as "Disposition to issuer." These were not open-market sales but forfeitures of unvested restricted shares.
Footnotes explain that the forfeited shares were tied to several time-vesting and performance-vesting restricted stock awards granted on March 8, 2023, March 6, 2024, March 17, 2025, and March 16, 2026. After these forfeitures, he continues to hold Common Stock directly and maintains significant option-based exposure.
His remaining derivative holdings include employee stock options to buy Common Stock with exercise prices ranging from $7.74 to $16.06 per share, expiring between 2031 and 2035, such as an option over 112,000 shares at $10.62 per share expiring in 2031.
inTest CORP reported proposed sale of Common Stock in a Form 144 notice. The filing lists a Restricted Stock Award vesting on 03/18/2026 for 16,754 shares and shows prior sales in the past three months of 1,097; 1,397; and 1,636 shares on March dates. The filing is a routine affiliate sale notice.
inTEST Corp ownership filing: an amendment to a Schedule 13G/A by The Vanguard Group states it beneficially owns 0 shares of inTEST Corp common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries or business divisions to report holdings separately, and affirms those entities now report disaggregated beneficial ownership in reliance on SEC Release No. 34-39538.
INTEST CORP director Steven J. Abrams reported a bona fide gift of 9,000 shares of Common Stock. On March 20, 2026, he transferred these shares to a family revocable trust for no consideration. He and his spouse are co-trustees and he remains the beneficial owner of the shares held by the trust.
After the transaction, he directly holds 12,000 shares and indirectly holds 96,000 shares through the Steven J. Abrams Revocable Trust, so his overall economic exposure to INTEST CORP stock is unchanged by this gift transfer.
INTEST CORP divisional president Richard B. Rogoff reported routine equity compensation activity and an RSU vesting. On March 17, 2026, 1,010 restricted stock units converted into the same number of common shares, and 253 common shares were withheld at $14.46 per share to cover tax obligations rather than sold on the market.
On March 16, 2026, he received grants under the 2023 Stock Incentive Plan, including 2,304 common shares, a further 2,304 performance-based restricted shares that may vest in March 2029 at target performance (with up to 3,456 shares possible), and a stock option for 3,895 shares at an exercise price of $14.47 expiring on March 15, 2036.
After these transactions, Rogoff directly held 12,152 common shares. He also retained multiple stock option positions shown in the filing, including options over 13,565 shares at an exercise price of $7.74 expiring on March 17, 2035 and 9,496 shares at $11.33 expiring on March 5, 2034.
INTEST CORP division president Michael F. Goodrich reported equity compensation grants and routine tax withholding. On March 16, 2026, he received 1,843 restricted shares and 1,843 performance-based restricted shares of Common Stock, both granted at $0.00 under the 2023 Stock Incentive Plan.
The performance-based award will vest in March 2029 based on performance criteria, with a maximum of 2,765 shares vesting at top performance. He also received an Employee Stock Option for 3,116 shares at an exercise price of $14.47 per share, expiring on March 15, 2036, vesting in four equal annual installments starting March 16, 2027.
On March 17, 2026, 216 shares of Common Stock were withheld at $14.46 per share to cover tax obligations on vesting restricted stock, leaving 23,155 shares held directly after this tax-withholding disposition. He also holds additional stock options with exercise prices of $7.74 and $11.33 per share, expiring in 2035 and 2034, respectively.
INTEST CORP Division President – Electronic Test, Joseph Richard McManus Jr., reported routine equity compensation changes and related tax withholding. He received 2,535 restricted shares and 2,535 performance-based restricted shares of Common Stock that were granted under the company’s 2023 Stock Incentive Plan and vest over multiple years, including installments starting on March 16, 2027 and potential vesting in March 2029 based on performance.
He also received an employee stock option covering 4,284 shares of Common Stock at an exercise price of $14.47 per share, expiring in 2036, which vests in four equal annual installments beginning on March 16, 2027. To cover tax obligations on the vesting of restricted stock on March 17, 2026, 296 shares of Common Stock were withheld at a price of $14.46 per share. After these transactions, he directly owns 35,693 Common shares and holds several option awards with exercise prices between $7.74 and $16.06 expiring between 2031 and 2035.
inTEST Corp CFO Duncan Gilmour reported equity compensation awards, not open-market trading. He received an employee stock option for 9,736 shares of common stock at an exercise price of $14.47 per share, expiring in 2036, which will vest in four equal annual installments starting March 16, 2027.
He was also granted 5,760 time-based restricted shares that vest in four equal annual installments beginning on March 16, 2027, plus 5,760 performance-based restricted shares that may vest in March 2029 if specified performance goals are met, with a maximum of 8,640 shares eligible to vest at peak performance.
Following these awards, Gilmour holds 67,954 shares of common stock directly and 200 shares indirectly through his spouse, along with multiple previously granted stock options with exercise prices between $7.74 and $16.80 expiring from 2031 through 2035.